





The 66th Annual Meeting of the Pacific Coast Reproductive Society MARCH 21 - 25, 2018 • Renaissance Hotel, Indian Wells, California

Title:

DOES THE NUMBER OF MATURE FOLLICLES IN OVULATION INDUCTION CYCLES AT THE TIME OF TRIGGER CORRELATE WITH MULTIPLE GESTATION RATE?

Authors:

T.G. Nazem^{1,2}; C. Hernandez-Nieto¹; L. Sekhon^{1,2}; Joseph A. Lee¹; D. Gounko¹; B. Sandler^{1,2}; A.B. Copperman^{1,2}

Affiliations:

- 1. Reproductive Medicine Associates of New York, 635 Madison Ave. 10th Floor New York, NY, United States, 10022
- 2. Department of OBGYN and Reproductive Science, Mount Sinai School of Medicine, Klingenstein Pavilion, 9th Floor 1176 Fifth Ave. New York, NY, United States, 10029

Background:

Ovulation induction (OI) cycles with oral medications such as clomiphene citrate and letrozole are common first line treatments for infertile patients. Striking a balance between over and under-stimulation during OI is essential in preventing multiple gestations while increasing chances of achieving a single, healthy pregnancy.

Objective:

This study sought to evaluate whether the number of mature follicles at the time of trigger in OI cycles with oral medications is correlated with the rate of multiple gestations.

Materials and Methods:

In this retrospective cohort study, patients who underwent OI using CC or letrozole followed by an intrauterine insemination from 2002-2017 were included. Patient and partner age, BMI, ovarian reserve testing, endometrial thickness at the time of trigger, gravidity, parity, and sperm source were recorded. Clinical pregnancy (CP) was confirmed by the presence of fetal cardiac







activity on ultrasound. Data was analyzed using a student's t-test, chi-squared and binary logistic regression model.

Results:

A total of 11,722 OI cycles were performed. There was no difference in patient age, BMI or ovarian reserve outcome between patients who had a multiple or singleton gestation. While not statistically significant, there was a trend toward a higher AMH level among patients who had a multiple gestation compared with those with singletons (5.88 vs 3.66, p=0.08). Multiple gestation rate did not differ among patients taking CC or letrozole (0.79% vs 0.6%, p=0.31). Likelihood of CP and ongoing pregnancy (OP) was higher among patients who had more mature follicles. When two or more follicles were present at the time of trigger, OP rates increased twofold (OR 2.34, 95% CI 1.40-3.90) and when there were three or more follicles, pregnancy rates increased threefold (OR 3.38, 95% CI 1.95-5.86). While there were significantly more mature follicles in patients who had a multiple gestation as compared with singleton (2.32 vs 1.93, p<0.001), after controlling for age, parity, and ovarian reserve markers, there was no difference in likelihood of multiple gestation based on the number of follicles present (2 follicles OR 2.74, 95% CI 0.79-9.47, \geq 3 follicles OR 2.31, 95% CI 0.63-8.46).

Conclusions:

While the presence of more than one mature follicle increases the likelihood of achieving an OP, additional mature follicles does not boost the rate of multiple gestations. Given the risks associated with multiple gestations, these results are particularly reassuring in the management of younger patients undergoing OI who have multi-follicular development.

Financial Support:

None







Table 1:

	Multiple Gestation	Singleton Gestation	P Value
	(n=87)	(n=880)	
Age (y)	33.9 ± 4.12	34.5 ± 3.98	NS
BMI (kg/m^2)	25.1 ± 6.14	24.4 ± 4.69	NS
Day 3 FSH (IU/mL)	7.71 ± 3.36	7.00 ± 2.42	0.08
Day 3 Estradiol (pg/mL)	53.6 ± 25.0	48.2 ± 18.9	0.08
Anti-mullerian Hormone	5.88 ± 5.60	3.66 ± 3.99	0.08
(pmol/L)			
Endometrial Thickness at	8.75 ± 1.59	8.74 ± 1.51	NS
time of trigger (mm)			
Previous number of	2.38 ± 2.18	2.26 ± 1.98	NS
Ovulation Induction cycles			
Gravidity	0.79 ± 1.08	1.29 ± 1.23	0.004
Parity	0.34 ± 0.60	0.64 ± 0.74	0.003
Partner Age	36.3 ± 4.56	36.6 ± 5.58	NS
Donor Sperm Source	12.7% (11/87)	8.5% (75/880)	NS
Total Number Follicles >	2.32 ± 1.02	1.93 ± 0.94	<0.001
18mm			

Table 2:

	Clomiphene Citrate	Letrozole	P Value
Clinical Pregnancy Rate	9.1% (806/8899)	9.6% (272/2823)	NS
Ongoing Pregnancy Rate	8.1% (723/8899)	8.6% (244/2823)	NS
Multiple Pregnancy Rate	0.79% (70/8899)	0.60% (17/2823)	NS